Jun 3 |
FibroGen Stock Is Surging After The Bell: What's Going On?
|
Jun 3 |
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
|
May 31 |
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
|
May 31 |
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
|
May 31 |
Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
|
May 31 |
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
|
May 31 |
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
|
May 30 |
Biohaven doses first subject in Phase I/II tumour treatment study
|
May 29 |
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
|
May 27 |
The Biggest Biotechnology Company in Europe
|